CAR T cell News and Research

RSS

ACGT awards $500,000 grant to advance strategies for treating solid tumors

With a $500,000 Research Grant from Alliance for Cancer Gene Therapy, Sidi Chen, PhD, assistant professor in the Department of Genetics and Systems Biology Institute at Yale School of Medicine and member of Yale Cancer Center, will advance a versatile and highly scalable strategy he's been developing and calling MAEGI -- Multiplexed Activation of Endogenous Genes as an Immunotherapy.

6 Oct 2020

CAR T cell therapy can predict treatment response in patients with large B-cell lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and develop side effects.

6 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

Researchers decipher how the immune system memorizes pathogens after an infection

The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen. Now, scientists at the University of Würzburg have deciphered new details of this process.

28 Sep 2020

NCCN's first patient and caregiver resource focused on childhood leukemia

The National Comprehensive Cancer Network today announced the publication of the organization's first patient and caregiver resource focused on a childhood cancer type.

23 Sep 2020

Research uncovers potential cause of neurotoxicity due to immunotherapy

New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB).

21 Sep 2020

UofL receives $11.5 million to accelerate the development of new immunotherapies

Cancer remains one of the most difficult and deadly challenges in human health, affecting Kentuckians at a higher rate than residents of any other state and killing more than 600,000 people each year in the U.S. alone.

14 Sep 2020

New dual CAR T cell immunotherapy shows enhanced therapeutic potency to fight HIV

A recent study published in the journal Nature Medicine, led by researchers Todd Allen, PhD, a professor of Medicine at Harvard Medical School and group leader at the Ragon Institute of MGH, MIT and Harvard, and Jim Riley, PhD, a professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, describes a new Dual CAR T cell immunotherapy that can help fight HIV infection.

31 Aug 2020

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU).

20 Aug 2020

Researchers identify drug that improves survival in critically ill COVID-19 patients

19 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.

28 Jul 2020

Novel label-free imaging method can differentiate active T cells from those off duty

T cells are the immune soldiers at the frontlines of the battle with infiltrating pathogens that seek to cause disease. A new study published in Nature Biomedical Engineering describes a novel label-free imaging technique that can differentiate active T cells from those off duty.

27 Jul 2020

First CAR T-cell therapy for mantle cell lymphoma receives FDA approval

Today's Food and Drug Administration approval of the first CAR T-cell therapy for mantle cell lymphoma represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.

24 Jul 2020

Combining two immunotherapies into a single treatment found to be more effective

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

23 Jul 2020

Monash University researchers pave way for affordable immunotherapies

Researchers from Monash University’s Institute of Pharmaceutical Sciences are paving the way for accessible and affordable cancer treatment by using powerful nanoscale tools to overcome the high costs and long lead-times associated with one of the world’s newest forms of immunotherapy: CAR-T cell therapy.

22 Jul 2020

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.

20 Jul 2020

How immune cells switch to attack mode

Unraveling a key motif: The T lymphocytes of the immune system work to destroy infected cells or cancer cells. To do so, they have to identify the threat: Molecules perceived as foreign - so-called antigens - bind to the T-cell receptor on the T cell surface.

20 Jul 2020

Promising new CAR T cell therapy results in exceptional patient recovery

In a clinical trial evaluating a novel immunotherapy option for cancer treatment, a child with rhabdomyosarcoma, a form of muscle cancer, that had spread to the bone marrow, showed no detectable cancer following treatment with chimeric antigen receptor (CAR) T cells that were engineered to target the HER2 protein on the surface of the cancer cells.

15 Jul 2020

Study identifies possible factors to predict severe toxicities in CAR T patients

Chimeric antigen receptor T-cell therapy (CAR T) has proved to be a valuable treatment option for patients with lymphoma who have failed other therapies. In clinical trials, the cellular immunotherapy was shown to provide durable remissions for nearly 40% of large B cell lymphoma patients.

15 Jul 2020

CAR T cell News and Research

ACGT awards $500,000 grant to advance strategies for treating solid tumors

CAR T cell therapy can predict treatment response in patients with large B-cell lymphoma

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Researchers decipher how the immune system memorizes pathogens after an infection

NCCN's first patient and caregiver resource focused on childhood leukemia

Research uncovers potential cause of neurotoxicity due to immunotherapy

UofL receives $11.5 million to accelerate the development of new immunotherapies

New dual CAR T cell immunotherapy shows enhanced therapeutic potency to fight HIV

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Researchers identify drug that improves survival in critically ill COVID-19 patients

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

Novel label-free imaging method can differentiate active T cells from those off duty

First CAR T-cell therapy for mantle cell lymphoma receives FDA approval

Combining two immunotherapies into a single treatment found to be more effective

Monash University researchers pave way for affordable immunotherapies

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

How immune cells switch to attack mode

Promising new CAR T cell therapy results in exceptional patient recovery

Study identifies possible factors to predict severe toxicities in CAR T patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News